HSE - PCRS

Application Details

HSE Application ID

HSE100018

HTA Number

25014

HTA Link

https://www.ncpe.ie/tislelizumab-tevimbra-hta-id-25014/

Drug

tislelizumab

Brand

Tevimbra®

Applicant

BeOne Medicines Ireland Limited

Indication Applied For

As monotherapy is indicated for the treatment of adult patients with unresectable, locally 
advanced or metastatic oesophageal squamous cell carcinoma (OSCC) after prior platinum-based chemotherapy.

Application Date

19/02/2025

Marketing Authorisation Date

15/09/2023

Application Status

Full Health Technology Assessment Commissioned by HSE

26/03/2025

Rapid Review Completed

04/03/2025

Pricing and Reimbursement Application Complete

19/02/2025

Rapid Review Commissioned

18/02/2025

New Search